Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074479" target="_blank" >RIV/65269705:_____/21:00074479 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/21:00121497

Result on the web

<a href="https://www.nature.com/articles/s41375-021-01173-w" target="_blank" >https://www.nature.com/articles/s41375-021-01173-w</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-021-01173-w" target="_blank" >10.1038/s41375-021-01173-w</a>

Result language

angličtina

Original language name

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Original language description

Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia

ISSN

0887-6924

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

8

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

2416-2418

UT code for WoS article

000618175800004

EID of the result in the Scopus database

2-s2.0-85101440931